Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHuPH20-facilitated SC IG in PIDD
NCT01485796Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2011
- Primary completion
- Jan 2013
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human hyaluronidase PH20 in primary immunodeficiency diseases (PID), sponsored by Takeda. Started Dec 2011; status: completed.
02
Drugs
recombinant human hyaluronidase PH20
03
Conditions
primary immunodeficiency diseases (PID)
Beyond the preview
Go deeper on NCT01485796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485796.